Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 13/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.43 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL806950 | 0.85 | POLRMT (0.59) | P2RY2IMPDH2P2RY1P2RX1P2RX3 | |
| SCHEMBL16479517 | 0.85 | POLRMT (0.59) | P2RY2IMPDH2P2RY1P2RX1P2RX3 | |
| SCHEMBL4763052 | 0.83 | P2RY2 (0.47) | P2RY2P2RY4P2RX1P2RX3 | |
| SCHEMBL19101783 | 0.80 | POLRMT (0.48) | P2RY2P2RY4GPR17P2RY1P2RY11 | |
| SCHEMBL807421 | 0.79 | HIF1A (0.41) | — | |
| SCHEMBL10153839 | 0.79 | POLRMT (0.61) | P2RY2P2RY4P2RY1P2RX1P2RX3 | |
| SCHEMBL16708590 | 0.78 | PNP (0.33) | — | |
| SCHEMBL20943584 | 0.78 | PNP (0.33) | — | |
| SCHEMBL16698714 | 0.77 | POLRMT (0.65) | P2RY2P2RY4GPR17P2RY1P2RY11 | |
| SCHEMBL20960138 | 0.77 | POLRMT (0.65) | P2RY2P2RY4GPR17P2RY1P2RY11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226140-A1 | 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170226140-A1 | 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20140200188-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2014-07-17 | — | — | US | disclosed |
| US-20140200188-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2014-07-17 | — | — | US | disclosed |
| US-20120107274-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120107274-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200188-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NSUN2, SLC29A2 | P2RY2 142/4885P2RY4 230/4885IMPDH2 26/4885 |
| US-20170226140-A1 | 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NUDT1, NSUN2 | P2RY2 147/4885P2RY4 233/4885IMPDH2 30/4885 |
| US-20120107274-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NUDT1, SLC29A2 | P2RY2 153/4885P2RY4 211/4885IMPDH2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.